FilingReader Intelligence
Shandong Lukang responds to exchange inquiry on land compensation
May 19, 2025 at 05:13 AM UTC•By FilingReader AI
Shandong Lukang Pharmaceutical (SSE:600789) has responded to the Shanghai Stock Exchange’s inquiry regarding its 2024 annual report, focusing on land compensation income. The company clarified land compensation proceeds, with CNY 152 million recorded as income, contributing 24% to the year’s net profit.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shandong Lukang Pharmaceutical publishes news
Free account required • Unsubscribe anytime